Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV Vaccine in Healthy Chinese Females
NCT05027776Phase 3Recruiting
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of quadrivalent human papillomavirus recombinant vaccine in human papillomavirus infection (3 arms), sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoint: Primary immunogenicity outcome at Month 8. Started Sep 2021; status: recruiting.
02
Drugs
quadrivalent human papillomavirus recombinant vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05027776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027776.